(Information sent by the signatory company)
IRVINE, Calif., May 7, 2024 /PRNewswire/ –Seragon Biosciences, Inc. today announced the completion of a preclinical study of its novel anti-aging candidate, SRN-901. This pivotal study, conducted in mice, was conducted to evaluate the impact of SRN-901 on aging as well as various health markers.
The study results show that SRN-901 achieved one of the largest life and health extensions to date in the treated population. Whole-genome transcriptome sequencing was performed on more than 300 mice to evaluate the effects of SRN-901 at the molecular level. The results highlighted a significant increase in the expression of many genes associated with longevity and a notable reduction in the expression of genes related to aging. Additionally, a metabolic panel revealed beneficial changes in several biomarkers associated with younger biological age.
Other tests were performed to evaluate the effect of SRN-901 on life expectancy, a measure of how long health is maintained throughout life. The study also assessed physical and cognitive function. Treadmill tests showed significantly greater endurance in elderly mice. Frailty scores showed a marked improvement in aged mice receiving SRN-901, and there was a significant reduction in tumor occurrence in the treated group.
The Seragon Biosciences research team is encouraged by the study results and will conduct further analysis to uncover additional findings. These results will be published once the supplemental analysis is completed.
About Seragon Biosciences
Seragon Biosciences, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Biosciences is committed to applying cutting-edge scientific and technological advances in the fields of aging, metabolism, gene therapy and bioinformatics. From research to consumer products and clinical applications, Seragon strives to provide people with access to the most important advances in medicine. For more information, visit www.seragon.com.
Logo – https://mma.prnewswire.com/media/1986399…
View original content: https://www.prnewswire.com/news-releases/seragon-completa-el-estudio-preclinico-del-candidato-a-intervencion-contra-el-envejecimiento-srn-901-302137969.html
